Determination of the rate of growth of the livers of living donors and recipients. The unique ability of the liver to regenerate to a predetermined size after resection or transplantation makes partial liver transplants possible. Much of what is known about hepatic regeneration is still poorly understood. A better understanding of the process will facilitate partial liver transplantation in many ways and bring it under some degree of external control. Regeneration and recovery can be hastened. Study objectives include: 1. Determination of the regeneration process following donation of a lobe or segment of liver. 2. To study the duration of regeneration process in the recipient following transplantations of partial livers. 3. To determine the effects of factors unique to transplantation on hepatic regeneration by comparison of the process in donors and recipients. 4. To study the relationship between the total mass resected or transplanted and the duration of regeneration process. 5. To determine if there is any reliable correlation between commonly measured serum proteins and the degree of hepatic regeneration. 6. To establish parameters for specific assessment of the function and adequacy of partial grafts during the period of regeneration. 7. To explore the possibility of manipulating the regenerative process to reduce the mass of liver necessary for a successful partial transplant and hasten post operative recovery. The study will involve approximately donors and recipients. All research will be carried out at the General Clinical Research Center. Participants will undergo standard evaluation which will be used for baseline information for the study. Subjects will have Magnetic Resonance Imaging (MRI) or Computed Tomography Scan (CT) several times after surgery to determine the rate of regrowth of donor liver and transplanted liver. Blood tests will also be done at these times to establish normal laboratory values.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
38
Fiscal Year
2000
Total Cost
$648
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8

Showing the most recent 10 out of 367 publications